OVERVIEW
Happy Saturday
Welcome To the Stocks Top 25 Newsletter this week!
The Stocks Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocks Top 25 Lists for this week:
S&P 500
Top 25 S&P 500
The S&P 500 Top 25 list 1.05%outperformed the S&P 500 index -0.63%
Newcomers are in blue. Grey names at the bottom were kicked out of last week’s list.
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list -1.19%outperformed the Nasdaq 100 index -1.93%
Newcomers are in blue. Grey names at the bottom were kicked out of last week’s list.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list 0.86%compared to the Russell 2000 index 1.19%
Newcomers are in blue. Grey names at the bottom were kicked out of last week’s list.
Top Dawg Of The Week
The Top 25 list's Top Dawg was Terns Pharmaceuticals flying over 52% after an early week report of a cancer treatment trial. $TERN ( ▼ 4.44% )
The company reported updated positive Phase 1 results for its experimental chronic myeloid leukemia CML drug, TERN-701.
The drug, an allosteric BCR::ABL1 inhibitor, achieved a high Major Molecular Response MMR rate of 64% by 24 weeks across all patients, and 75% in the higher dose groups. This efficacy is considered unprecedented, trending two to three times higher than competitor drugs.
The trial also showed a strong safety profile with no dose-limiting toxicities, supporting the company’s plan to advance TERN-701 directly into Phase 2 development.
Like many startups, TERNs is spending cash on research hand over foot, according to Fiscal.ai